for placebo-treated and 4.9 cm 3 for IFNβ-1b-treated Recently, the clinical efficacy of interferon β-1b (IFNβ-patients (P ⍧ 0.56). Placebo-treated patients showed an 1b) was demonstrated for secondary progressive (SP) increase in T 1 lesion load by a median of 14% per year multiple sclerosis in a European multicentre study. We (P ⍧ 0.0002 compared with baseline); this was reduced to evaluated the effect of IFNβ-1b treatment on the rate of 7.7% per year in the IFNβ-1b-treated patients (P ⍧ 0.003 development of hypointense T 1 MRI lesions, a putative versus placebo). In the IFNβ-1b arm there was a marker of axonal damage. Unenhanced T 1 -weighted statistically significant correlation between absolute images were obtained in a subgroup of 95 multiple change in Expanded Disability Status Scale scores and T 1 sclerosis patients from five centres at 6-month intervals; lesion load by month 36 (r ⍧ 0.38, P ⍧ 0.0015). In this subgroup was similar to the total study population patients with SP multiple sclerosis, IFNβ-1b treatment for all demographic, clinical and MRI parameters. An reduces the development of hypointense T 1 lesions, experienced observer blinded to the clinical data and suggesting that reduced axonal damage in lesions may treatment allocation measured volumes. The median play a part in the beneficial effect that is observed clinically. baseline lesion load for hypointense T 1 lesions was 5.1 cm 3
Introduction
Several types of interferon β have been shown to be partially 1b in secondary progressive multiple sclerosis, 1998), which showed delayed development of sustained progression, a effective in the treatment of relapsing-remitting (RR) multiple sclerosis (Paty and Li, 1993 ; Multiple Sclerosis Collaborative lower relapse rate and reduced MRI evidence of disease. Frequent MRI showed a continuously reduced rate of Research Group, 1996; Li and Paty, 1999) . Recently, efficacy of interferon β-1b (IFNβ-1b) was also demonstrated for development of active lesions, and the T 2 lesion load measured in annual scans of all patients was reduced secondary progressive (SP) multiple sclerosis in a European multicentre study (European Study Group on interferon betacompared with baseline (Miller et al., 1999) , a result quite similar to that found for RR patients (Paty and Li, 1993 ; Li whether our subset differed from the full study with regard to T 2 lesion load or active lesions. and Paty, 1999) .
The mechanisms that lead to relapse and MRI lesion activity may be similar in RR and SP patients, and the congruent results of interferon treatment in the two subtypes
MR imaging protocol and image analysis
The data used for this study comprised unenhanced T 1 -may therefore not come as a surprise. With regard to the development of disability, RR patients predominantly suffer weighted images obtained before the administration of gadolinium. All five centres operated at 1.5 T. T 1 -weighted from incomplete recovery from relapses, while SP patients, by definition, also suffer from chronic progression images were obtained using a spin-echo sequence with a repetition time between 400 and 600 ms and echo time independently of relapses. In SP patients, the development of disability is likely to result from more pronounced progressive between 5 and 25 ms, using 5 mm slices and 1 mm in-plane resolution. To obtain a contiguous data set of 24 slices, two axonal loss, either in lesions or in the form of widespread non-focal disease.
interleaved series of 12 slices each were acquired. On these T 1 -weighted images, hypointense lesions were marked using To gain further insight into the biological mechanisms underlying the slowing of progression in SP patients on IFNβ-a mouse-controlled cursor on the electronic data by a single experienced observer. Lesion hypointensity was defined as a 1b therapy, we evaluated the development of hypointense MRI lesions under treatment. In comparison with RR multiple signal clearly lower than the surrounding white matter, but not necessarily lower than the grey matter. Identification of sclerosis, hypointense T 1 lesions are more prevalent in SP patients and correlate better with disability than hyperintense lesions was done by checking, for each lesion that was visible on a T 2 -weighted image, whether it was hypointense on the T 2 lesions (Truyen et al., 1996) . Data from post-mortem studies (van Waesberghe et al., 1999) and in vivo magnetic corresponding T 1 -weighted image. The observer marked all scans of a given patient consecutively in order to reduce resonance spectroscopy (van Walderveen et al., 1999) indicate that lesion hypointensity is strongly correlated with axonal observer variability, but without knowledge of clinical data and treatment allocation. The marked lesions were then density, and it is thus well suited to address the rate of development of axonal loss in multiple sclerosis. In this quantified by another observer on the electronic MRI data using home-developed software based on seeding and local paper we report the effect of IFNβ-1b treatment on the rate of development of hypointense lesions in SP multiple thresholding, and the result was multiplied by the interslice distance to obtain volumetric data; the intra-observer variation sclerosis.
for the quantification is 5% (Truyen et al., 1996) . These observers were fully blinded to the clinical data and treatment allocation.
Material and methods
This study was performed in a subgroup of 95 multiple sclerosis patients participating in a large European,
Statistical analysis
multicentre, randomized, double-blind, placebo-controlled Data were entered into a database by an independent contract trial (Polman et al., 1995;  European Study Group on interferon research organization (independent from the sponsor) and beta-1b in secondary progressive multiple sclerosis, 1998). checked for consistency. Therefore, even though the analyses In brief, patients with SP multiple sclerosis were randomized were performed after unblinding of the study, the analyses to receive Schering, Berlin, Germany) were performed in a strictly blinded fashion. Statistical 8 MIU, subcutaneously on alternate days, or placebo analyses were performed for both absolute and percentage injections. The study was approved by the Ethical Committees changes in hypointense lesion load compared with baseline. of the participating centres, and all patients gave informed
Analyses include all patients with data available at baseline consent. The full study included 718 patients, all of whom and at least once during treatment. All data available at underwent yearly conventional T 2 -weighted imaging; in a any given point in time were evaluated with missing data subset of 125 patients from seven centres, frequent maintained as missing. In additional analyses, missing data gadolinium-enhanced images were also obtained (Miller were imputed by linear interpolation; because these yielded et al., 1999) . In five of those centres (Amsterdam, Milan, the same results, only data without replacement are presented Munich, Würzburg and London), additional unenhanced T 1 -in this report. Furthermore, changes in hypointense lesion weighted images were obtained at 6-month intervals to assess load at individual last visits (last scan available) were the development of hypointense lesions. Clinical disability evaluated. was measured at 3-month intervals using the Expanded
Comparisons of baseline data between groups were Disability Status Scale (EDSS) score by the assessing performed using the Wilcoxon rank-sum test and Fisher's physician, who was blinded to treatment-related activities exact test. To assess changes in hypointense lesion load from (Polman et al., 1995) . The T 2 -weighted and gadoliniumbaseline within treatment groups, the paired t test was used. enhanced MRI results have been reported previously (Miller Comparisons between groups were performed using nonparametric analysis of covariance with stratification et al., 1999), and we used the existing database to assess adjustment for centre and covariance adjustment for baseline the analysis performed on the full data set (European Study Group on interferon beta-1b in secondary progressive multiple lesion load. To assess the association between T 1 hypointense lesion load and EDSS, non-parametric (Goodman-Kruskal) sclerosis, 1998). The median baseline lesion load for hypointense T 1 lesions correlation coefficients were calculated; because we assumed that changes in data for month 6 may have been confounded was 5.1 cm 3 for the placebo group and 4.9 cm 3 for the IFNβ-1b patients (P ϭ 0.56). Both arms showed a linear increase by temporary hypointense lesions (and minor fluctuations in EDSS), assessments were correlated from month 12 onwards.
in lesion load across time (Table 2 ). In the placebo-treated patients, this increase was significant from month 6 onwards; by month 36 they had increased their T 1 lesion load by a median value of 2.43 cm 3 , corresponding to a median change
Results
For seven patients no valid T 1 data were available and for from baseline of 41.8% (P ϭ 0.0002 compared with baseline), with an average an increase of 14% per annum (Fig. 1) . The three others the baseline value was missing, leaving 85 valid cases for analysis, 41 on placebo, 44 on IFNβ-1b. Table 1 IFNβ-1b patients also showed a linear increase from baseline, which became statistically significant at month 18 for the shows that the demographics and baseline descriptive findings of those patients were similar to those of the total study first time, and by month 36 the median increase in lesion load was 0.76 cm 3 , corresponding to a median change from population, indicating that no major selection bias had occurred. Also, none of the baseline descriptive data differed baseline of 23.2% (P ϭ 0.006), with an average increase of 7.7% per annum. The rate of increase in T 1 hypointense between placebo and verum at the 5% significance level. For T 2 lesion load, there was a median increase of 4.19 cm 3 lesion load was significantly slower in the IFNβ-1b treated patients than in the placebo-treated group (P ϭ 0.0003). This (17.5%) at month 36 in the placebo group, whereas the IFNβ-1b group showed a median decrease of 0.35 (4.0%) at was also true when individual last-scan data were analysed (P ϭ 0.0001, adjusted value for treatment effect between month 36 (P Ͻ 0.0001 between groups). At month 36, the median cumulative number of new or enlarged lesions on groups). The correlations between absolute change in T 1 lesion load T 2 -weighted images was 7 in the placebo group and 1 in the IFNβ-1b group (P ϭ 0.038). Similarly, highly significant and EDSS are reported in Table 3 . For the whole group, there was a positive correlation (r ϭ 0.28 at month 36, P ϭ differences favouring the IFNβ-1b group were seen in the numbers of enhancing lesions during the monthly scanning 0.007). Within the individual arms, the correlations were weak in the placebo arm, whereas statistically significant blocks for months 1-6 and 19-24 (P Ͻ 0.0005 between groups for both periods). All these data are consistent with correlations were found in the IFNβ-1b arm from month 12 II) trials (Miller et al., 1996) . However, given the uncertain (Miller et al., 1996) . duration of follow-up, the lack of histopathological specificity beyond the inflammatory stage (identified by gadolinium enhancement) is a major weakness of MRI. On T 2 -weighted images, almost any alteration in brain tissue composition will lead to increased signal, including oedema, partial demyelination, gliosis and axonal loss. There is evidence that even remyelinated lesions may return high signal on these T 2 -weighted images ('t Hart et al., 1998; van Walderveen et al., 1998) . This could explain the poor correlation with clinical disability, which is likely to be determined mainly by axonal loss. There are several magnetic resonance techniques with improved histopathological specificity, including magnetic resonance spectroscopy, magnetization transfer and T 1 hypointensity. In this study we evaluated the significant treatment effect, even though a clear trend was suggested (Simon et al., 2000) . effect of IFNβ-1b treatment on T 1 hypointensity as a marker of matrix destruction and axonal loss in progressive multiple Both post-mortem MRI data (van Waesberghe et al., 1999) and in vivo magnetic resonance spectroscopy data (van sclerosis (van Walderveen et al., , 1999 van Waesberghe et al., 1999) . Walderveen et al., 1999; Brex et al., 2000) indicate that the degree of T 1 hypointensity relates to the amount of axonal The subset of patients presented here is comparable with the full data set (European Study Group on interferon damage (resulting in widening of extracellular space, with more free, slowly relaxing water). The smaller increase in beta-1b in secondary progressive multiple sclerosis, 1998), indicating that no significant selection bias occurred and that T 1 hypointense lesion load in the IFNβ-1b group in our SP multiple sclerosis study indicates less progression of axonal the treatment arms were well matched. Valid T 1 data were available for the vast majority of patients. The T 1 lesion load loss in lesions. As axonal loss is the most likely correlate of clinical progression, our findings are comparable with the at baseline was slightly higher than in an earlier study on the natural history of multiple sclerosis (Truyen et al., 1996) , moderate clinical effect of 40% reduction in time to progression (12 months delay after a median time on study in which a median volume of 3.0 cm 3 was reported for SP multiple sclerosis patients, who progressed to 4.15 cm 3 after of 18 months (European Study Group on interferon beta1b in secondary progressive multiple sclerosis, 1998). The an average of 3.5 years. The increase of 12% per annum in that natural course study is similar to the increase in lesion causality between these two measures is suggested by the finding of positive correlation coefficients in the IFNβ-1b load in the placebo arm of the present study (42% over 3 years). The finding of an expected pattern of behaviour in arm; the absence of similar correlations in the placebo arm could be explained by more relapse-related changes in the placebo arm is an essential element in the interpretation of randomized controlled trials (Li and Paty, 1999) .
disability. The fact that even in the IFNβ-1b arm the correlations are still modest indicates that other mechanisms In studies of SP multiple sclerosis, the increase in T 1 hypointense lesion load may seem large with respect to the leading to disability (e.g. diffuse disease leading to atrophy) may still be at play. increase in T 2 lesion load (Truyen et al., 1996) ; in our study the median increase in T 1 hypointense lesion load was
The 45% reduction in development in T 1 hypointense lesions is closer to the clinical effect size than the enormous 2.43 cm 3 , while the T 2 hyperintense lesion load increased by a median of 4.19 cm 3 . This may reflect three phenomena. effect seen on T 2 lesion load; the latter even showed a slight decrease in lesion load in the IFNβ-1b arm after 3 years First, the net change in lesion load is derived from an increase by new lesions and shrinkage by others (Lee et al., 1998) , a (Miller et al., 1999) . The overestimation of the treatment effect on T 2 lesion load relates to an initial decrease in phenomenon that is much less plausible for T 1 hypointense lesions. Secondly, progressive damage in pre-existing lesions lesion load, which has been a consistent finding in previous interferon studies (Paty and Li, 1993; Li and Paty, 1999) . has been demonstrated (Rocca et al., 1999) , suggesting that ongoing axonal damage may occur in pre-existing lesions, This probably reflects the resolution of oedematous and inflammatory changes caused by active lesions present at especially in patients with SP multiple sclerosis, which may eventually lead to hypointensity on T 1 -weighted SE images.
baseline, and the subsequent increase in T 2 lesion load during the trial is too small to offset this initial dip. A similar Lastly, the relatively small lesion load at baseline compared with the T 2 -hyperintense lesion load may influence the phenomenon is not detectable for the development of T 1 hypointensity using this 6-monthly analysis, even though increase in T 1 hypointense lesion load, expressed as a percentage. The latter phenomenon may also explain the monthly studies have noted that a percentage of lesions may become hypointense initially ; findings in patients with RR multiple sclerosis, with a yearly increase of 14.5% per year (Simon et al., 2000) , the low Rovira et al., 1999) . However, the vast majority of the temporary hypointense lesions revert to isointensity after 1 lesion load at baseline (median 0.64 cm 3 ) providing a small denominator.
or 2 months, which probably explains why lesion load measurements of unenhanced and gadolinium-enhanced In the IFNβ-1b-treated arm, the increase in T 1 lesion load was significantly lower than in the placebo arm (P ϭ 0.0003), images (where acutely hypointense lesions are masked by their enhancement) show an extremely high correlation with a 45% reduction in the increase in T 1 hypointense lesion load. This is the first parallel-design controlled study to (O'Riordan et al., 1998) . Therefore, in this study, with a low sampling rate (relative to the duration of enhancement and demonstrate a therapeutic effect on this MRI parameter in SP multiple sclerosis patients. An effect on the development oedema of new multiple sclerosis lesions), we are confident that the increase in hypointense lesions measured in this of hypointense lesions has also been noted in a phase II trial of interferon alpha-1a in RR multiple sclerosis, in which study was not due to temporary hypointensity (with marked oedema), but rather to the development of chronic 'black patients served as their own controls (Gasperini et al., 1999) . In this phase II study, a lower percentage of new lesions on holes' (with axonal loss). Previous studies in SP multiple sclerosis have shown a T 2 -weighted images with persistent hypointensity on T 1 -weighted images was suggested (Paolillo et al., 1999a) . A relationship between change in the T 1 hypointense load and the rate of atrophy (Paolillo et al., 1999b) . The fact that such phase III trial with interferon alpha-1a failed to find a Prevention of relapses and disability by interferon-beta1a measures are correlated indicates that both are (indirect) subcutaneously in multiple sclerosis. Ann Neurol 1999; 46: 197-206. measures of axonal damage. On the other hand, the correlations are far from perfect, indicating that severe tissue Miller ( Coles et al. 1999; Filippi et al., 2000) . 
